Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
26 sept. 2024 07h14 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
26 sept. 2024 07h00 HE
|
Mural Oncology, Inc.
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...
EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy
26 sept. 2024 07h00 HE
|
EnnoDC
PRESS RELEASE EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy Versatile new technology featuring an...
Teleflex’s Barrigel Rectal Spacer to Be Featured in Three Presentations at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting
26 sept. 2024 06h30 HE
|
Teleflex Incorporated
• Highlights include new safety and efficacy data of Barrigel™ rectal spacer, the first and only sculptable rectal spacer1-3 • Teleflex to host Barrigel™ Educational Symposium featuring a physician...
AB Science fait aujourd'hui le point sur le programme microtubule AB8939 et en particulier sur la capacité d'AB8939 à générer une réponse sur le réarrangement du gène MECOM
26 sept. 2024 02h28 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LE PROGRAMME MICROTUBULE AB8939 ET EN PARTICULIER SUR LA CAPACITÉ D’AB8939 À GÉNÉRER UNE RÉPONSE SUR LE REARRANGEMENT DU GENE MECOM Paris, 26...
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
26 sept. 2024 02h28 HE
|
AB Science
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT Paris, 26 September 2024, 8.30am CET...
Boehringer Ingelheim expands cancer research at its Vienna site
25 sept. 2024 10h45 HE
|
Boehringer Ingelheim
Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost of EUR 60 million offers modern office and laboratory spaceOver the past five years, Boehringer’s...
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
25 sept. 2024 08h30 HE
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
25 sept. 2024 08h30 HE
|
RenovoRx, Inc.
LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies based on a...
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
24 sept. 2024 11h09 HE
|
Tevogen Bio Inc
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...